On November 18,as the MEDICA 2025 exhibition entered its second day,the atmosphere was lively and the venue was bustling with crowds.That morning,at the ChoiceMMed booth(HALL 10 C50)in the Düsseldorf Exhibition Center in Germany,Lawrence Wang,General Manager of ChoiceMMed,accepted an on-site exclusive interview with MEDICA.

"Prevention and Management"Healthcare System 

Lawrence pointed out in the interview that ChoiceMMed has built a health closed loop from early warning and diagnosis to intervention and management,centered around two major pathways:"pre-hospital prevention"and"post-hospital management."With pulse oxygen technology at its core,the company has formed a product matrix encompassing three major lines:pulse oximetry,respiratory care,and cardiovascular care,achieving strategic synergy.It is committed to providing users with integrated health solutions ranging from home monitoring to chronic disease management.

Quiet Oxygen Concentrator Technology Attracts Attention 

At this MEDICA exhibition,ChoiceMMed showcased multiple core products featuring innovative technologies,including pulse oximeters in various forms such as fingertip,handheld,wrist,and tabletop models,as well as innovative pulse oximetry products supporting Bluetooth and 4G remote transmission.Furthermore,ChoiceMMed highlighted its breakthrough achievements in quiet oxygen concentration technology.The newly upgraded intelligent medical oxygen concentrator operates at noise levels below 42 decibels and supports intelligent start/stop linkage with pulse oximeter products,which attracted a large number of professional visitors to stop and experience it.

Technology Empowers Remote Health 

Regarding cutting-edge trends such as artificial intelligence and telemedicine,Lawrence stated that ChoiceMMed has already established a remote health platform covering"pre-hospital early warning-post-hospital management."Through technologies like cuffless blood pressure monitoring,single-lead ECG acquisition,and arrhythmia analysis,the company is integrating professional medical capabilities into portable,wearable remote medical devices.It is also building a continuous user data collection system to help users achieve early risk screening and ongoing health intervention in home settings. 

Deepening European Presence 

When discussing international market expansion,Lawrence emphasized that the MEDICA exhibition is a key platform for ChoiceMMed's European market strategy.Using ChoiceMMed Germany as a pivot point,the company is deepening local services and brand building.Aligning with local market demands,it is focusing on deploying competitive intelligent products to deeply explore the German and EU markets.

Through this exhibition and interview exchange,ChoiceMMed not only demonstrated its comprehensive capabilities in the fields of health monitoring and intelligent chronic disease management to the global market but also further clarified its direction of driving product innovation through"smart technology manufacturing."Driven by core technology R&D,ChoiceMMed will navigate the vast future blue ocean of healthcare,bringing more professional,intelligent,and considerate health guardianship to global users.